Cyberonics Invests in German Firm Cerbomed Houston, Texas-based Cyberonics Inc. is making an initia

Cyberonics Invests in German Firm Cerbomed
Houston, Texas-based Cyberonics Inc. is making an initial investment of 2 million euros in Cerbomed GmbH, a privately held company in Erlangen, Germany, that is developing a non-invasive neurostimulation device for the treatment of epilepsy. Its Nemos t-VNS device received CE Mark approval for the treatment of epilepsy and depression in 2010 and for pain in 2012; it now is commercially available both in Germany and Austria.

Cyberonics also develops products for the treatment and management of epilepsy. The 25-year-old company’s core expertise is in neuromodulation.

The investment in Cerbomed may total up to 5.5 million euros and is subject to the achievement of certain clinical milestones. Cyberonics is a minority shareholder with certain rights, including representation on Cerbomed’s advisory board and an exclusive option for worldwide sales and distribution of the Nemos system for the treatment of epilepsy. The initial investment will be used to fund Cerbomed’s current clinical trial in epilepsy in Germany. Cyberonics has the option to conduct a trial in the United States to gain Food and Drug Administration approval, if desired.

“As a company focused on device solutions for epilepsy, an investment in Cerbomed’s technology is aligned with our strategic priorities and core expertise,” said Dan Moore, Cyberonics’ president and CEO. “We are excited about the opportunity to invest in a technology that may provide more patients with epilepsy another device-based therapeutic option and opportunity for improved quality of life.”
“We are delighted to welcome Cyberonics as our strategic global partner for the epilepsy indication,” added Cerbomed CEO Andreas Hartlep. “We look forward to our collaboration and continuing to understand how transcutaneous and implantable vagus nerve stimulation may be complementary technologies and provide benefit to patients.”

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters